Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago CAR-T

2024 ASCO: National Institute’s New CAR-T Therapy CD7 CAR-T Cells, Multiple Blood Cancer Destroyers

CAR-T Therapy

2024 ASCO: Four Chinese-developed CAR-T therapies make a significant impact, targeting colorectal cancer, pancreatic cancer, and hematological tumors, with an overall response rate nearing 100.0%

CD7 CAR-T Cells: A Powerful Strike Against Hematological Tumors, Patients Achieve Complete Remission

Patients with relapsed or refractory hematologic malignancies have limited treatment options and poor prognosis, with a 5-year overall survival rate of less than 20%. While allogeneic hematopoietic stem cell transplantation (HSCT) provides a critical strategy for treating aggressive hematologic cancers, HSCT treatment can also result in adverse reactions such as graft-versus-host disease (GVHD) and conditioning-related toxicities. Additionally, some patients with poor health cannot undergo this treatment. Therefore, new treatment methods are urgently needed, and the emergence of CAR-T therapy has brought new hope to patients with hematologic tumors.

The world-renowned journal, The New England Journal of Medicine, reported on a clinical study of “CD7 CAR-T cells for the treatment of relapsed or refractory CD7-positive hematologic tumors” (NCT04599556).

From November 2021 to September 2023, 10 patients with relapsed or refractory CD7-positive cancers were enrolled in the study, including 7 cases of acute myeloid leukemia (AML), 2 cases of T-cell acute lymphoblastic leukemia (ALL), and 1 case of T-cell lymphoblastic lymphoma (IVA stage). The median age was 56.5 years (range, 13.7–72.5 years). All patients had bone marrow involvement, with a median blast cell percentage of 36.0% (range, 2–87), and a median CD7 expression on blast cells of 93.0% (range, 80.7–97.7). All patients had received extensive prior treatments, with a median of 9.5 courses (range, 4–15 courses). After enrollment, patients first received an intensive lymphocyte-depleting regimen (cyclophosphamide, fludarabine, etoposide) and then CD7 CAR-T cell infusion therapy. After a median follow-up of 15.1 months, the results showed:

**Complete Remission (CR):** All patients (n=10) achieved complete remission (CR) after CAR-T cell therapy, though hematologic recovery was incomplete, with grade 4 pancytopenia. As of November 8, 2023 (data cutoff date), 6 patients had not received any further treatment and remained in minimal residual disease (MRD) negative complete remission.

**Overall Survival Rate:** The estimated 1-year overall survival rate was 68% [95% Confidence Interval (CI), 43–100].

**Disease-Free Survival Rate:** The estimated 1-year disease-free survival rate was 54% (95% CI, 29–100).

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#ASCO2024 #CARTherapy #BloodCancer #CD7CART #CancerResearch #Hematology #MedicalInnovation #CART

9 months ago CAR-T

Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology

🔬 Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology 🔬

Nature

The clinical research achievements conducted by Professor Huang He’s team from the First Affiliated Hospital of Zhejiang University School of Medicine have been published online in the top international journal Nature under the title “Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.”

In the field of CAR-T cells, we face numerous challenges. However, the collaboration between Professor Liu Mingyao’s team and Director Huang He’s team has introduced the innovative CRISPR/Cas9 gene editing technology into CAR-T therapy, bringing us unprecedented breakthroughs. They precisely utilized CRISPR/Cas9 technology to remove the “brake” PD1 from T lymphocytes and inserted the targeted CD19 CAR molecule for tumor cells, creating a brand-new non-viral targeted integration CAR-T cell (PD1-19bbz).

💡 Analyzing the Scientific Principles behind the Technology 💡

CRISPR/Cas9 can be likened to a “gene editing scissors,” with PD1 being the “brake” on T cells. By precisely removing the PD1 locus with the “scissors” and inserting the “GPS navigation system” CD19 CAR molecule at the same position, we successfully eliminated the “brake” of CAR-T cells, turning them into efficient killers targeting tumors.

🧬 Groundbreaking Clinical Validation 🧬

Through rigorous clinical studies, we have confirmed the safety and efficacy of PD1-19bbz. Whether in tumor cells with high or low PD-L1 expression, PD1-19bbz has demonstrated more powerful and durable killing effects. What’s more exciting is that our research indicates PD1-19bbz achieves a 100% objective response rate and an 87.5% complete response rate in treating refractory relapsed lymphoma patients.

🌟 Pioneering a New Era in CAR-T Cell Therapy 🌟

This groundbreaking achievement brings new hope to CAR-T cell therapy. We have successfully established a brand-new CAR-T cell technology platform, providing a safer and more effective option for the treatment of refractory relapsed lymphoma and other diseases. This also signifies the leading position of Chinese scholars in the field of CAR-T cell research and development internationally.

💬 Expert Evaluation 💬

Professor Justin Eyquem from the University of California and Senior Editor Victoria Aranda from Nature highly praised our achievements: “This inspiring result demonstrates the excellent clinical safety and efficacy of this CAR-T therapy.”

We will continue to dedicate ourselves to advancing CAR-T cell therapy, bringing hope and health to more patients. Stay tuned for our progress!

🧶You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:

🌈🌈📩doctor.huang@globecancer.com🌈🌈,

or click on the ☎️WhatsApp+8613717959070☎️ icon on the homepage.

The Medical Department will contact you as soon as they receive the reports.

#CARTCells #CRISPR #ScientificBreakthrough #CancerTreatment

9 months ago CAR-T

World’s First! Chinese Tongji Hospital Successfully Treats Immune-Mediated Necrotizing Myopathy with CAR-T Cells!

🎉🔬✨ World’s First! Chinese Tongji Hospital Successfully Treats Immune-Mediated Necrotizing Myopathy with CAR-T Cells! ✨🔬🎉

PNAS

🌟A groundbreaking achievement in medicine! Immune-Mediated Necrotizing Myopathy

Professor Wang Wei’s team from Tongji Hospital, affiliated with Huazhong University of Science and Technology, has brought unprecedented hope to patients with immune-mediated necrotizing myopathy. 🌟

📅 On January 30th, their research was published in the prestigious journal “Proceedings of the National Academy of Sciences” (PNAS). They utilized CAR-T cells targeting mature B cell antigen (BCMA) for the first time, achieving significant clinical efficacy in treating immune-mediated necrotizing myopathy. This research opens new avenues for treating this condition, marking a historic breakthrough in medicine.

ℹ️ CAR-T cell therapy

is a gene-editing cellular treatment method. Patient’s own T cells are extracted, genetically modified in vitro to possess targeted killing capabilities. These modified CAR-T cells are then reintroduced into the patient’s body to selectively eliminate target cells, bringing about dramatic changes in the disease’s progression.

Tongji

👨‍⚕️ Patient Mr. Deng is a successful case of CAR-T cell therapy. Diagnosed with immune-mediated necrotizing myopathy seven and a half years ago, his condition worsened over time, leaving him bedridden. After receiving CAR-T treatment, his health significantly improved, he successfully entered graduate school for medical studies, achieved full recovery, discontinued all immunosuppressive drugs, and now lives medication-free. This is a remarkable victory! 💪

🌈 What’s even more surprising is that several patients treated with CAR-T cells experienced the regrowth of new B cells approximately one year post-treatment. These new B cells exhibit a completely different phenotype, and pathogenic antibodies in the patients’ bodies completely disappear, achieving a joyful “immune reshaping.”

🌍 This breakthrough research brings hope to autoimmune disease patients worldwide.

Professor Wang Wei’s team’s efforts have paved the way for new treatment approaches, offering a fresh start for patients once deemed untreatable. We look forward to the global adoption of this treatment method, benefiting more patients worldwide. Let’s cheer for this remarkable achievement together! 👏

In addition to lung cancer, we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:
doctor.huang@globecancer.com,
or click on the
WhatsApp+8613717959070.

The Medical Department will contact you as soon as they receive the reports.🌟

#CARTCellTherapy #ImmuneMediated #NecrotizingMyopathy #MedicalBreakthrough #TongjiHospital #ScientificResearch #MedicalRevolution #HealthHope #myopathy

Menu

Tags Archives: CAR-T Cells

2024 ASCO: National Institute’s New CAR-T Therapy CD7 CAR-T Cells, Multiple Blood Cancer Destroyers